Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
46.7M
-
Number of holders
-
139
-
Total 13F shares, excl. options
-
46.8M
-
Shares change
-
-11M
-
Total reported value, excl. options
-
$261M
-
Value change
-
-$76.3M
-
Put/Call ratio
-
0.27
-
Number of buys
-
72
-
Number of sells
-
-70
-
Price
-
$5.57
Significant Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) as of Q4 2024
170 filings reported holding FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) has 139 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.8M shares
.
Largest 10 shareholders include BlackRock, Inc. (4.92M shares), RA CAPITAL MANAGEMENT, L.P. (4.56M shares), GOLDMAN SACHS GROUP INC (4.27M shares), VR Adviser, LLC (2.95M shares), VANGUARD GROUP INC (2.86M shares), BVF INC/IL (2.67M shares), JANUS HENDERSON GROUP PLC (2.25M shares), MORGAN STANLEY (1.86M shares), Novo Holdings A/S (1.5M shares), and MILLENNIUM MANAGEMENT LLC (1.42M shares).
This table shows the top 139 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.